| |
Redefine what it means to be inspection-ready with Premier’s Inspection Readiness Program. This four-phase plan will arm you with the knowledge, skills, and confidence to successfully host health authority inspections. Get started with our brochure. 
|
|
Today’s Big NewsOct 24, 2024 |
|
The deal will help Jubilant Biosys expand its footprints in Europe for drug discovery and pre-clinical offerings in areas like biologics and ADC on top of existing integrated drug discovery services & CDMO from India. .png)
|
|
| By Angus Liu In a new deal potentially worth more than $1 billion, Roche is paying Dyno $50 million upfront to design novel adeno-associated virus vectors as delivery tools for gene therapies against neurological diseases. |
|
|
|
By Darren Incorvaia Between the two companies, more than 560 people joined trials without being told they had a heightened risk of dangerous side effects such as brain bleeding or swelling, The New York Times reported. |
By Nick Paul Taylor Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, linking its hereditary angioedema prospect to an 81% reduction in monthly attacks in a phase 2 trial. |
Sponsored by Travere Therapeutics When a specialized field of medicine has long been quiet, a buzz of breakthrough can seem like a sudden development. The reality is more nuanced. |
|
- 45 markers for cytokine signaling/inflammation
- Trust RBM for Olink, Luminex & Simoa immunoassays
|
|
By Nick Paul Taylor Lundbeck is slashing the book value of its $250 million Abide Therapeutics buyout in response to phase 1 data that triggered an early end to a pain program. |
Sponsored by TriNetX, Inc. Now’s the time to rethink clinical trials with real-world data (RWD). Discover strategies to optimize your protocols and site selection. |
By Fraiser Kansteiner Shortly after Bicara Therapeutics raised more than $360 million in an IPO, the cancer biotech and its former parent company have been hit with accusations of intellectual property theft. |
By Kevin Dunleavy Preliminary results from two trials showed that GSK’s RSV vaccine Arexvy has potential in a broad age range of immunocompromised and other at-risk individuals, potentially positioning the shot for a larger population. |
By Darren Incorvaia Massachusetts-based tech company Revvity has launched a new tool to remove a data entry chore from clinical laboratories. |
By Paige Minemyer LAS VEGAS—Demand for GLP-1s has not slowed, and employers still have not cracked the code on the perfect solution for medications that represent a growing portion of spend. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," we examine why diverse viewpoints are essential for tackling the industry’s toughest challenges and how building real engagement serves as the bedrock for innovation. |
|
|---|
|
|
Whitepaper Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
